Changelog
Last 14 days
2026-02-20
2026-02-20
MRK
Merck & Co., Inc.
Status: COMPLETED → TERMINATED (Study was closed early due to slow enrollment.) — PHASE2
NCT03990961
• Phase 2 • Status: Completed → Terminated • Why stopped: Study was closed early due to slow enrollment.
🚩 MAJOR
2026-02-20
C
CHCO
CITY HOLDING CO
Status: NOT_YET_RECRUITING → WITHDRAWN (withdrawn) — PHASE1
NCT07061574
• Phase 1 • Status: Not yet recruiting → Withdrawn • Why stopped: withdrawn
🚩 MAJOR
2026-02-20
O
ONON
On Holding AG
CT.gov status: ENROLLING_BY_INVITATION → SUSPENDED (Potential study redesign) — NA — investigator-sponsored (collaborator: ONON)
NCT06505993
• Na • Status: Enrolling by invitation → Suspended • Why stopped: Potential study redesign
HIGH
2026-02-20
C
CHCO
CITY HOLDING CO
Primary endpoint added: Total Perioperative Opioid Consumption — NA
NCT06808737
• Na
MEDIUM
2026-02-20
H
HLN
Haleon plc
Primary endpoint added: Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough — PHASE4
NCT06716645
• Phase 4
MEDIUM
2026-02-20
C
CRNX
Crinetics Pharmaceuticals, Inc.
Locations updated — PHASE3
NCT07087054
• Phase 3
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE1
NCT06845202
• Phase 1
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT06393712
• Phase 2
MEDIUM
2026-02-20
H
HSY
HERSHEY CO
Enrollment 900→297 (-67%)
NCT06444542
• Enrollment 900→297 (-67%)
MEDIUM
2026-02-20
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07015905
• Phase 3
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE1
NCT07214727
• Phase 1
MEDIUM
2026-02-20
Z
ZLDPF
Zealand Pharma A/S/ADR
Status: NOT_YET_RECRUITING → RECRUITING — PHASE3
NCT07197944
• Phase 3 • Status: Not yet recruiting → Recruiting
MEDIUM
2026-02-20
U
UNTC
UNIT CORP
Enrollment 50000→117000 (134%) — NA
NCT05676541
• Na • Enrollment 50000→117000 (+134%)
MEDIUM
2026-02-20
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Locations updated — PHASE3
NCT06611163
• Phase 3
MEDIUM
2026-02-20
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT06291376
• Phase 3
MEDIUM
2026-02-20
M
MIRM
Mirum Pharmaceuticals, Inc.
Locations updated — PHASE2
NCT07209462
• Phase 2
MEDIUM
2026-02-20
NVS
NOVARTIS AG
Enrollment 14082→14111 (0%) — PHASE3
NCT05739383
• Phase 3 • Enrollment 14082→14111 (+0%)
MEDIUM
2026-02-20
S
SO
SOUTHERN CO
Enrollment 160→140 (-12%) — NA
NCT06361914
• Na • Enrollment 160→140 (-12%)
MEDIUM
2026-02-20
U
UNTC
UNIT CORP
Enrollment 120→122 (2%) — PHASE1
NCT05385510
• Phase 1 • Enrollment 120→122 (+2%)
MEDIUM
2026-02-20
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07144852
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07181109
• Phase 3
MEDIUM
2026-02-20
O
ONON
On Holding AG
Primary endpoint added: Evaluate Uptake of Pre-exposure Prophylaxis (PrEP) — NA
NCT06187064
• Na
MEDIUM
2026-02-20
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT07175428
• Phase 2
MEDIUM
2026-02-20
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Locations updated — PHASE3
NCT07144852
• Phase 3
MEDIUM
2026-02-20
C
CRNX
Crinetics Pharmaceuticals, Inc.
Locations updated — PHASE2
NCT07159841
• Phase 2
MEDIUM
2026-02-20
O
ONON
On Holding AG
Primary endpoint added: Number and Percentage of Participants With Documented Current Use of MOUD at Week 26 by Site — NA
NCT04804072
• Na
MEDIUM
2026-02-20
C
CHCO
CITY HOLDING CO
Enrollment 120→0 (-100%) — PHASE1
NCT07061574
• Phase 1 • Enrollment 120→0 (-100%)
MEDIUM
2026-02-20
NVS
NOVARTIS AG
Enrollment 432→443 (3%) — PHASE2
NCT06780670
• Phase 2 • Enrollment 432→443 (+3%)
MEDIUM
2026-02-20
R
RLAY
Relay Therapeutics, Inc.
Enrollment 18→10 (-44%) — PHASE1
NCT06460844
• Phase 1 • Enrollment 18→10 (-44%)
MEDIUM
2026-02-20
C
CTMX
CytomX Therapeutics, Inc.
Enrollment 124→160 (29%) — PHASE1
NCT06265688
• Phase 1 • Enrollment 124→160 (+29%)
MEDIUM
2026-02-19
2026-02-19
AZN
ASTRAZENECA PLC
Status: RECRUITING → SUSPENDED (As a part of portfolio and planning reassessment for the cur)
NCT07247292
• Status: Recruiting → Suspended • Why stopped: As a part of portfolio and planning reassessment for the current period, a decision has been made to prioritize, optimiz…
🚩 MAJOR
2026-02-19
O
ONON
On Holding AG
Enrollment 345→180 (-48%) — NA
NCT05492825
• Na • Enrollment 345→180 (-48%)
MEDIUM
2026-02-19
O
ONON
On Holding AG
Primary endpoint removed: Health-related quality of life — NA
NCT05492825
• Na
MEDIUM
2026-02-19
T
TISI
TEAM INC
Primary endpoint added: Change in Montreal Cognitive Assessment (MoCA) — NA
NCT06936514
• Na
MEDIUM
2026-02-19
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT05644561
• Phase 3
MEDIUM
2026-02-19
BSX
BOSTON SCIENTIFIC CORP
Enrollment 20→5 (-75%) — NA
NCT05938283
• Na • Enrollment 20→5 (-75%)
MEDIUM
2026-02-19
AZN
ASTRAZENECA PLC
Enrollment 4→14 (250%) — PHASE3
NCT06512883
• Phase 3 • Enrollment 4→14 (+250%)
MEDIUM
2026-02-19
C
CADL
Candel Therapeutics, Inc.
Enrollment 30→45 (50%) — PHASE2
NCT07332000
• Phase 2 • Enrollment 30→45 (+50%)
MEDIUM
2026-02-19
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07144345
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
2026-02-19
C
CADL
Candel Therapeutics, Inc.
Primary endpoint removed: Biomarkers of immune activation and tumor burden — PHASE2
NCT07332000
• Phase 2
MEDIUM
2026-02-19
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Locations updated — PHASE3
NCT07144345
• Phase 3
MEDIUM
2026-02-19
BSX
BOSTON SCIENTIFIC CORP
Enrollment 500→524 (5%)
NCT06656884
• Enrollment 500→524 (+5%)
MEDIUM
2026-02-19
NVS
NOVARTIS AG
Enrollment 285→288 (1%) — PHASE3
NCT05624749
• Phase 3 • Enrollment 285→288 (+1%)
MEDIUM
2026-02-19
M
MRUS
Merus N.V.
Enrollment 576→194 (-66%) — PHASE1
NCT04868877
• Phase 1 • Enrollment 576→194 (-66%)
MEDIUM
2026-02-19
O
OCGN
Ocugen, Inc.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06388200
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-19
AZN
ASTRAZENECA PLC
Primary endpoint added: Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants — PHASE3
NCT05555732
• Phase 3
MEDIUM
2026-02-19
AZN
ASTRAZENECA PLC
Enrollment 192→120 (-38%) — PHASE2
NCT06450197
• Phase 2 • Enrollment 192→120 (-38%)
MEDIUM
2026-02-19
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT06246916
• Phase 3
MEDIUM
2026-02-18
2026-02-18
O
ONON
On Holding AG
Status: RECRUITING → SUSPENDED (The trial is currently paused during a move to a new institu) — EARLY_PHASE1
NCT05829655
• Early_Phase 1 • Status: Recruiting → Suspended • Why stopped: The trial is currently paused during a move to a new institution and acquisition of the new IRB approval at University o…
🚩 MAJOR
2026-02-18
ABBV
AbbVie Inc.
Primary endpoint added: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA] — PHASE3
NCT05248880
• Phase 3
MEDIUM
2026-02-18
PFE
PFIZER INC
Enrollment 400→412 (3%) — PHASE3
NCT05911295
• Phase 3 • Enrollment 400→412 (+3%)
MEDIUM
2026-02-18
MRK
Merck & Co., Inc.
Enrollment 390→326 (-16%) — PHASE2
NCT03742895
• Phase 2 • Enrollment 390→326 (-16%)
MEDIUM
2026-02-18
AZN
ASTRAZENECA PLC
Enrollment 55000→52121 (-5%)
NCT06355934
• Enrollment 55000→52121 (-5%)
MEDIUM
2026-02-18
V
VRDN
Viridian Therapeutics, Inc.\DE
Status: ACTIVE_NOT_RECRUITING → COMPLETED — PHASE3
NCT06384547
• Phase 3 • Status: Active, not recruiting → Completed
MEDIUM
2026-02-18
A
AMPL
Amplitude, Inc.
Enrollment 120→115 (-4%) — NA
NCT06457685
• Na • Enrollment 120→115 (-4%)
MEDIUM
2026-02-18
BMY
BRISTOL MYERS SQUIBB CO
Enrollment 117→147 (26%) — PHASE1
NCT06121843
• Phase 1 • Enrollment 117→147 (+26%)
MEDIUM
2026-02-18
I
IMVT
Immunovant, Inc.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT05517447
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-18
VTRS
Viatris Inc
Status: NOT_YET_RECRUITING → RECRUITING — PHASE3
NCT07201129
• Phase 3 • Status: Not yet recruiting → Recruiting
MEDIUM
2026-02-18
D
DNTH
Dianthus Therapeutics, Inc. /DE/
Locations updated — PHASE3
NCT06858579
• Phase 3
MEDIUM
2026-02-18
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT06787612
• Phase 2
MEDIUM
2026-02-18
ABBV
AbbVie Inc.
Primary endpoint added: Number of Participants with Adverse Events (AEs) — PHASE3
NCT04161898
• Phase 3
MEDIUM
2026-02-18
SNY
Sanofi
Enrollment 1630→1714 (5%) — PHASE3
NCT06736041
• Phase 3 • Enrollment 1630→1714 (+5%)
MEDIUM
2026-02-18
O
ONON
On Holding AG
Enrollment 24→27 (12%) — NA
NCT04054050
• Na • Enrollment 24→27 (+12%)
MEDIUM
2026-02-18
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE4
NCT07221838
• Phase 4
MEDIUM
2026-02-18
AZN
ASTRAZENECA PLC
Enrollment 60→12 (-80%) — PHASE2
NCT05137262
• Phase 2 • Enrollment 60→12 (-80%)
MEDIUM
2026-02-18
A
ALC
ALCON INC
Enrollment 161→188 (17%) — NA
NCT06444516
• Na • Enrollment 161→188 (+17%)
MEDIUM
2026-02-18
MRK
Merck & Co., Inc.
Primary endpoint added: Maximum Concentration (Cmax) of DOR Following Once-Daily Dosing in Plasma at Steady-State — PHASE2
NCT04375800
• Phase 2
MEDIUM
2026-02-17
2026-02-17
BIIB
BIOGEN INC.
Status: ACTIVE_NOT_RECRUITING → TERMINATED (Sponsor Decision) — PHASE2
NCT05798520
• Phase 2 • Status: Active, not recruiting → Terminated • Why stopped: Sponsor Decision
🚩 MAJOR
2026-02-17
GILD
GILEAD SCIENCES, INC.
Status: ACTIVE_NOT_RECRUITING → TERMINATED (Sponsor Decision) — PHASE2
NCT05629208
• Phase 2 • Status: Active, not recruiting → Terminated • Why stopped: Sponsor Decision
🚩 MAJOR
2026-02-17
M
MGNX
MACROGENICS INC
CT.gov status: NOT_YET_RECRUITING → SUSPENDED (PI requested) — PHASE2 — investigator-sponsored (collaborator: MGNX)
NCT07071961
• Phase 2 • Status: Not yet recruiting → Suspended • Why stopped: PI requested
HIGH
2026-02-17
C
CORT
CORCEPT THERAPEUTICS INC
Enrollment 1000→1143 (14%)
NCT06829537
• Enrollment 1000→1143 (+14%)
MEDIUM
2026-02-17
I
IDYA
IDEAYA Biosciences, Inc.
Primary endpoint added: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: — PHASE2
NCT05987332
• Phase 2
MEDIUM
2026-02-17
N
NVMI
NOVA LTD.
Enrollment 670→509 (-24%) — NA
NCT03682991
• Na • Enrollment 670→509 (-24%)
MEDIUM
2026-02-17
B
BHVN
Biohaven Ltd.
Enrollment 10→20 (100%) — PHASE1
NCT07054684
• Phase 1 • Enrollment 10→20 (+100%)
MEDIUM
2026-02-17
I
IDYA
IDEAYA Biosciences, Inc.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE2
NCT05987332
• Phase 2 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-17
O
ONON
On Holding AG
Enrollment 100→101 (1%) — NA
NCT06595030
• Na • Enrollment 100→101 (+1%)
MEDIUM
2026-02-17
A
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07037771
• Phase 3
MEDIUM
2026-02-17
C
CNTB
Connect Biopharma Holdings Ltd
Locations updated — PHASE2
NCT06940154
• Phase 2
MEDIUM
2026-02-17
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07052903
• Phase 3
MEDIUM
2026-02-17
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE4
NCT07221838
• Phase 4
MEDIUM
2026-02-17
C
CNTB
Connect Biopharma Holdings Ltd
Locations updated — PHASE2
NCT06940141
• Phase 2
MEDIUM
2026-02-17
O
ONON
On Holding AG
Study arms updated — NA — investigator-sponsored (collaborator: ONON)
NCT05530460
• Na
MEDIUM
2026-02-17
O
ONON
On Holding AG
Enrollment 124→135 (9%) — NA
NCT05747703
• Na • Enrollment 124→135 (+9%)
MEDIUM
2026-02-17
O
ONON
On Holding AG
Enrollment 130→15 (-88%) — NA
NCT07271290
• Na • Enrollment 130→15 (-88%)
MEDIUM
2026-02-17
NVS
NOVARTIS AG
Enrollment 108→109 (1%) — PHASE3
NCT05888493
• Phase 3 • Enrollment 108→109 (+1%)
MEDIUM
2026-02-17
Z
ZLDPF
Zealand Pharma A/S/ADR
Enrollment 92→124 (35%) — PHASE1
NCT06682975
• Phase 1 • Enrollment 92→124 (+35%)
MEDIUM
2026-02-17
S
SNDX
Syndax Pharmaceuticals Inc
Primary endpoint added: Number of participants with dose-limiting toxicities (DLTs) (Phase 1) — PHASE1
NCT04065399
• Phase 1
MEDIUM
2026-02-17
S
SNDX
Syndax Pharmaceuticals Inc
Enrollment 413→447 (8%) — PHASE1
NCT04065399
• Phase 1 • Enrollment 413→447 (+8%)
MEDIUM
2026-02-17
BMY
BRISTOL MYERS SQUIBB CO
Enrollment 400→418 (4%)
NCT06851065
• Enrollment 400→418 (+4%)
MEDIUM
2026-02-17
ABBV
AbbVie Inc.
Enrollment 74→73 (-1%) — PHASE1
NCT06774313
• Phase 1 • Enrollment 74→73 (-1%)
MEDIUM
2026-02-17
NVS
NOVARTIS AG
Enrollment 564→1214 (115%)
NCT05344469
• Enrollment 564→1214 (+115%)
MEDIUM
2026-02-16
No high/medium-impact events.
2026-02-15
No high/medium-impact events.
2026-02-14
No high/medium-impact events.
2026-02-13
2026-02-13
NVS
NOVARTIS AG
Enrollment 203→206 (1%) — PHASE2
NCT04589650
• Phase 2 • Enrollment 203→206 (+1%)
MEDIUM
2026-02-13
P
PHVS
Pharvaris N.V.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06669754
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-13
O
ONON
On Holding AG
Study arms updated — NA — investigator-sponsored (collaborator: ONON)
NCT06957743
• Na
MEDIUM
2026-02-13
MDT
Medtronic plc
Enrollment 50→100 (100%) — NA
NCT05144503
• Na • Enrollment 50→100 (+100%)
MEDIUM
2026-02-13
NVS
NOVARTIS AG
Enrollment 47→49 (4%) — PHASE2
NCT05849298
• Phase 2 • Enrollment 47→49 (+4%)
MEDIUM
2026-02-13
C
CHCO
CITY HOLDING CO
Enrollment 100→120 (20%) — PHASE4
NCT07333859
• Phase 4 • Enrollment 100→120 (+20%)
MEDIUM
2026-02-13
AZN
ASTRAZENECA PLC
Study arms updated — PHASE2 — investigator-sponsored (collaborator: AZN)
NCT02693535
• Phase 2
MEDIUM
2026-02-13
G
GMAB
GENMAB A/S
Enrollment 424→195 (-54%) — PHASE1
NCT04623541
• Phase 1 • Enrollment 424→195 (-54%)
MEDIUM
2026-02-13
NVS
NOVARTIS AG
Enrollment 165→163 (-1%) — PHASE4
NCT03975829
• Phase 4 • Enrollment 165→163 (-1%)
MEDIUM
2026-02-13
NVO
NOVO NORDISK A S
Status: ACTIVE_NOT_RECRUITING → COMPLETED — PHASE3
NCT04596631
• Phase 3 • Status: Active, not recruiting → Completed
MEDIUM
2026-02-13
N
NVAX
NOVAVAX INC
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07079670
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
2026-02-13
N
NVAX
NOVAVAX INC
Enrollment 120→676 (463%) — PHASE3
NCT07079670
• Phase 3 • Enrollment 120→676 (+463%)
MEDIUM
2026-02-13
MRK
Merck & Co., Inc.
Enrollment 30→34 (13%) — PHASE1
NCT06814119
• Phase 1 • Enrollment 30→34 (+13%)
MEDIUM
2026-02-13
A
AVDL
AVADEL PHARMACEUTICALS PLC
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06525077
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-13
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE1
NCT06162572
• Phase 1
MEDIUM
2026-02-13
REGN
REGENERON PHARMACEUTICALS, INC.
Enrollment 176→74 (-58%) — PHASE1
NCT06162572
• Phase 1 • Enrollment 176→74 (-58%)
MEDIUM
2026-02-12
2026-02-12
M
MRBK
Meridian Corp
Status: RECRUITING → TERMINATED (recruitment challenges) — NA
NCT06897618
• Na • Status: Recruiting → Terminated • Why stopped: recruitment challenges
🚩 MAJOR
2026-02-12
PFE
PFIZER INC
Status: COMPLETED → TERMINATED (Closed due to slow accrual) — PHASE2
NCT03913559
• Phase 2 • Status: Completed → Terminated • Why stopped: Closed due to slow accrual
🚩 MAJOR
2026-02-12
K
KPTI
Karyopharm Therapeutics Inc.
Study arms updated — PHASE2
NCT05980806
• Phase 2
HIGH
2026-02-12
NVS
NOVARTIS AG
Enrollment 50→22 (-56%) — PHASE2
NCT02934568
• Phase 2 • Enrollment 50→22 (-56%)
MEDIUM
2026-02-12
F
FDMT
4D Molecular Therapeutics, Inc.
Locations updated — PHASE3
NCT07064759
• Phase 3
MEDIUM
2026-02-12
F
FDMT
4D Molecular Therapeutics, Inc.
Enrollment 400→480 (20%) — PHASE3
NCT07064759
• Phase 3 • Enrollment 400→480 (+20%)
MEDIUM
2026-02-12
R
RXRX
RECURSION PHARMACEUTICALS, INC.
Enrollment 165→230 (39%) — PHASE1
NCT05985655
• Phase 1 • Enrollment 165→230 (+39%)
MEDIUM
2026-02-12
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT06465329
• Phase 2
MEDIUM
2026-02-12
NVS
NOVARTIS AG
Enrollment 46→47 (2%) — PHASE2
NCT05849298
• Phase 2 • Enrollment 46→47 (+2%)
MEDIUM
2026-02-12
A
AMPE
Ampio Pharmaceuticals, Inc.
Primary endpoint added: Number of Participants With a 50 Percent Decrease in Mean Stool Count — PHASE4
NCT03898856
• Phase 4
MEDIUM
2026-02-12
C
CHCO
CITY HOLDING CO
Enrollment 37→31 (-16%) — NA
NCT05443347
• Na • Enrollment 37→31 (-16%)
MEDIUM
2026-02-12
R
RYTM
RHYTHM PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT06760546
• Phase 3
MEDIUM
2026-02-12
R
RYTM
RHYTHM PHARMACEUTICALS, INC.
Enrollment 20→18 (-10%) — PHASE2
NCT06772597
• Phase 2 • Enrollment 20→18 (-10%)
MEDIUM
2026-02-12
K
KPTI
Karyopharm Therapeutics Inc.
Locations updated — PHASE2
NCT05980806
• Phase 2
MEDIUM
2026-02-12
F
FDMT
4D Molecular Therapeutics, Inc.
Locations updated — PHASE1
NCT05197270
• Phase 1
MEDIUM
2026-02-12
K
KPTI
Karyopharm Therapeutics Inc.
Enrollment 118→58 (-51%) — PHASE2
NCT05980806
• Phase 2 • Enrollment 118→58 (-51%)
MEDIUM
2026-02-12
AMGN
AMGEN INC
Enrollment 100→102 (2%) — PHASE4
NCT06332014
• Phase 4 • Enrollment 100→102 (+2%)
MEDIUM
2026-02-12
M
MRBK
Meridian Corp
Enrollment 50→40 (-20%) — NA
NCT06897618
• Na • Enrollment 50→40 (-20%)
MEDIUM
2026-02-12
O
ONON
On Holding AG
Primary endpoint added: Change in youth firearm violence involvement — NA
NCT06940362
• Na
MEDIUM
2026-02-12
F
FULC
Fulcrum Therapeutics, Inc.
Enrollment 70→45 (-36%) — PHASE1
NCT05169580
• Phase 1 • Enrollment 70→45 (-36%)
MEDIUM
2026-02-12
F
FULC
Fulcrum Therapeutics, Inc.
Locations updated — PHASE1
NCT05169580
• Phase 1
MEDIUM
2026-02-12
A
AARD
Aardvark Therapeutics, Inc.
Locations updated — PHASE3
NCT06828861
• Phase 3
MEDIUM
2026-02-12
Z
ZURA
Zura Bio Ltd
Enrollment 180→225 (25%) — PHASE2
NCT06993610
• Phase 2 • Enrollment 180→225 (+25%)
MEDIUM
2026-02-11
2026-02-11
MDT
Medtronic plc
Status: RECRUITING → TERMINATED (PI left the institution. IRB study closure date of 11/12/202) — NA
NCT06775886
• Na • Status: Recruiting → Terminated • Why stopped: PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.
🚩 MAJOR
2026-02-11
NVS
NOVARTIS AG
Enrollment 181→155 (-14%) — PHASE1
NCT07190300
• Phase 1 • Enrollment 181→155 (-14%)
MEDIUM
2026-02-11
MDT
Medtronic plc
Enrollment 40→60 (50%) — NA
NCT06703489
• Na • Enrollment 40→60 (+50%)
MEDIUM
2026-02-11
BSX
BOSTON SCIENTIFIC CORP
Enrollment 30→60 (100%) — NA
NCT06747013
• Na • Enrollment 30→60 (+100%)
MEDIUM
2026-02-11
PFE
PFIZER INC
Enrollment 32→5 (-84%) — PHASE2
NCT03913559
• Phase 2 • Enrollment 32→5 (-84%)
MEDIUM
2026-02-11
Z
ZNTL
Zentalis Pharmaceuticals, Inc.
Locations updated — PHASE2
NCT05128825
• Phase 2
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Enrollment 35→30 (-14%) — EARLY_PHASE1
NCT06824155
• Early_Phase 1 • Enrollment 35→30 (-14%)
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Locations updated — EARLY_PHASE1
NCT06824155
• Early_Phase 1
MEDIUM
2026-02-11
O
ONON
On Holding AG
Enrollment 55→70 (27%) — NA
NCT05810025
• Na • Enrollment 55→70 (+27%)
MEDIUM
2026-02-11
AZN
ASTRAZENECA PLC
Enrollment 10000→9000 (-10%)
NCT06521229
• Enrollment 10000→9000 (-10%)
MEDIUM
2026-02-11
G
GMAB
GENMAB A/S
Primary endpoint removed: Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Shifts From Baseline in Safety Laboratory Parameters — PHASE1
NCT03917381
• Phase 1
MEDIUM
2026-02-11
D
DAN
DANA Inc
Enrollment 76→32 (-58%) — PHASE2
NCT06366347
• Phase 2 • Enrollment 76→32 (-58%)
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Enrollment 23→30 (30%) — EARLY_PHASE1
NCT06305962
• Early_Phase 1 • Enrollment 23→30 (+30%)
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Locations updated — EARLY_PHASE1
NCT06305962
• Early_Phase 1
MEDIUM
2026-02-11
NVS
NOVARTIS AG
Enrollment 36→24 (-33%) — PHASE1
NCT05944562
• Phase 1 • Enrollment 36→24 (-33%)
MEDIUM
2026-02-11
A
ACAD
ACADIA PHARMACEUTICALS INC
Locations updated — PHASE2
NCT07284667
• Phase 2
MEDIUM
2026-02-11
AMGN
AMGEN INC
Primary endpoint added: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — PHASE3
NCT03362177
• Phase 3
MEDIUM
2026-02-11
NVO
NOVO NORDISK A S
Enrollment 3400→3439 (1%)
NCT04972721
• Enrollment 3400→3439 (+1%)
MEDIUM
2026-02-11
MDT
Medtronic plc
Enrollment 40→1 (-98%) — NA
NCT06775886
• Na • Enrollment 40→1 (-98%)
MEDIUM
2026-02-11
R
RVMD
Revolution Medicines, Inc.
Locations updated — PHASE3
NCT06881784
• Phase 3
MEDIUM
2026-02-10
2026-02-10
A
AUPH
Aurinia Pharmaceuticals Inc.
Status: RECRUITING → TERMINATED (DSMB recommendation) — PHASE3
NCT05288855
• Phase 3 • Status: Recruiting → Terminated • Why stopped: DSMB recommendation
🚩 MAJOR
2026-02-10
U
UTHR
UNITED THERAPEUTICS Corp
Status: ACTIVE_NOT_RECRUITING → COMPLETED — PHASE3
NCT04708782
• Phase 3 • Status: Active, not recruiting → Completed
MEDIUM
2026-02-10
P
PTCT
PTC THERAPEUTICS, INC.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT05166161
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-10
A
ARVN
ARVINAS, INC.
Enrollment 112→255 (128%) — PHASE1
NCT06393738
• Phase 1 • Enrollment 112→255 (+128%)
MEDIUM
2026-02-10
ABBV
AbbVie Inc.
Enrollment 258→268 (4%) — PHASE2
NCT07145918
• Phase 2 • Enrollment 258→268 (+4%)
MEDIUM
2026-02-10
ABBV
AbbVie Inc.
Primary endpoint added: Number of Participants Experiencing Adverse Events — PHASE3
NCT05711394
• Phase 3
MEDIUM
2026-02-10
O
ONON
On Holding AG
Enrollment 378→196 (-48%) — NA
NCT05736666
• Na • Enrollment 378→196 (-48%)
MEDIUM
2026-02-10
C
CL
COLGATE PALMOLIVE CO
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06365047
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-10
U
UTHR
UNITED THERAPEUTICS Corp
Enrollment 576→598 (4%) — PHASE3
NCT04708782
• Phase 3 • Enrollment 576→598 (+4%)
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Locations updated — PHASE1
NCT06162221
• Phase 1
MEDIUM
2026-02-10
A
AUPH
Aurinia Pharmaceuticals Inc.
Enrollment 40→9 (-78%) — PHASE3
NCT05288855
• Phase 3 • Enrollment 40→9 (-78%)
MEDIUM
2026-02-10
A
AUPH
Aurinia Pharmaceuticals Inc.
Locations updated — PHASE3
NCT05288855
• Phase 3
MEDIUM
2026-02-10
REGN
REGENERON PHARMACEUTICALS, INC.
Enrollment 150→151 (1%) — PHASE2
NCT06190951
• Phase 2 • Enrollment 150→151 (+1%)
MEDIUM
2026-02-10
M
MRBK
Meridian Corp
Study arms updated — PHASE2 — investigator-sponsored (collaborator: MRBK)
NCT03954236
• Phase 2
MEDIUM
2026-02-10
C
CLDX
Celldex Therapeutics, Inc.
Enrollment 120→131 (9%) — PHASE2
NCT06727552
• Phase 2 • Enrollment 120→131 (+9%)
MEDIUM
2026-02-10
A
ALC
ALCON INC
Primary endpoint added: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — PHASE3
NCT06544707
• Phase 3
MEDIUM
2026-02-10
MRK
Merck & Co., Inc.
Study arms updated — NA — investigator-sponsored (collaborator: MRK)
NCT07217262
• Na
MEDIUM
2026-02-10
N
NRC
NATIONAL RESEARCH CORP
Enrollment 224→178 (-21%) — NA
NCT05017779
• Na • Enrollment 224→178 (-21%)
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Enrollment 210→534 (154%) — PHASE1
NCT06128551
• Phase 1 • Enrollment 210→534 (+154%)
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Primary endpoint added: Changes in vital signs in Phase 1b — PHASE1
NCT06128551
• Phase 1
MEDIUM
2026-02-10
R
RVMD
Revolution Medicines, Inc.
Locations updated — PHASE1
NCT06128551
• Phase 1
MEDIUM
2026-02-10
C
CHCO
CITY HOLDING CO
Enrollment 190→176 (-7%)
NCT07100158
• Enrollment 190→176 (-7%)
MEDIUM
2026-02-09
2026-02-09
E
ECOR
electroCore, Inc.
Enrollment 2→3 (50%) — NA
NCT04935697
• Na • Enrollment 2→3 (+50%)
MEDIUM
2026-02-09
T
TELA
TELA Bio, Inc.
Enrollment 133→173 (30%) — NA
NCT07070115
• Na • Enrollment 133→173 (+30%)
MEDIUM
2026-02-09
O
ONON
On Holding AG
Enrollment 150→74 (-51%) — NA
NCT04064463
• Na • Enrollment 150→74 (-51%)
MEDIUM
2026-02-09
O
OLMA
Olema Pharmaceuticals, Inc.
Locations updated — PHASE3
NCT07085767
• Phase 3
MEDIUM
2026-02-09
GILD
GILEAD SCIENCES, INC.
Enrollment 45→36 (-20%) — PHASE1
NCT06071767
• Phase 1 • Enrollment 45→36 (-20%)
MEDIUM
2026-02-09
VTRS
Viatris Inc
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT05672576
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-09
VTRS
Viatris Inc
Enrollment 420→451 (7%) — PHASE3
NCT05672576
• Phase 3 • Enrollment 420→451 (+7%)
MEDIUM
2026-02-09
G
GSCCF
ioneer Ltd
Enrollment 1372→2350 (71%)
NCT05117788
• Enrollment 1372→2350 (+71%)
MEDIUM
2026-02-09
N
NRC
NATIONAL RESEARCH CORP
Enrollment 60→58 (-3%) — PHASE1
NCT06705530
• Phase 1 • Enrollment 60→58 (-3%)
MEDIUM
2026-02-09
MFG
MIZUHO FINANCIAL GROUP INC
Primary endpoint added: Rate of permanent aneurysm occlusions
MEDIUM
2026-02-09
O
ONON
On Holding AG
Primary endpoint removed: TB treatment completion rates after release from prison using a visual analog scale (VAS) — NA
NCT03089983
• Na
MEDIUM
2026-02-09
O
ONON
On Holding AG
Enrollment 1702→316 (-81%) — NA
NCT03089983
• Na • Enrollment 1702→316 (-81%)
MEDIUM
2026-02-09
MDT
Medtronic plc
Enrollment 515→516 (0%) — NA
NCT04075500
• Na • Enrollment 515→516 (+0%)
MEDIUM
2026-02-09
S
STOK
Stoke Therapeutics, Inc.
Enrollment 150→170 (13%) — PHASE3
NCT06872125
• Phase 3 • Enrollment 150→170 (+13%)
MEDIUM
2026-02-09
S
SO
SOUTHERN CO
Enrollment 360→131 (-64%) — NA
NCT03904186
• Na • Enrollment 360→131 (-64%)
MEDIUM
2026-02-09
AZN
ASTRAZENECA PLC
Enrollment 103→104 (1%) — PHASE1
NCT06132841
• Phase 1 • Enrollment 103→104 (+1%)
MEDIUM
2026-02-08
No high/medium-impact events.
2026-02-07
No high/medium-impact events.